This research is being done in participants who have Hepatocellular Carcinoma (HCC), also referred to as Liver Cancer, to evaluate how 3 drugs work in combination, and which dose is the best to treat your disease. The 3 drugs are casdozokitug (casdozo-key-tug), toripalimab (tor-i-pal-i- mab) and bevacizumab (bev-uh-siz-oo-mab). Toripalimab and bevacizumab have been approved by the Food and Drug Administration (FDA) to treat other cancers, but not Liver cancer. Casdozokitug has not been approved by the FDA to treat any cancers.
Thank you for your interest, but this study will start enrolling soon.
North Carolina (Statewide)
Jingquan Jia
Medicine- Oncology
Clinical or Medical
Interventional
Cancer (Colorectal)
Kidneys and Liver
24-3054
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
